Tris trial is registered with FDA with number: NCT01325701. The sponsor of the trial is Pharmacyclics LLC. and it is looking for 78 volunteers for the current phase.
Official trial title:
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)